Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Category: Patent Legislation
-
By Kevin E. Noonan — Just when you thought it was safe to stop worrying about the stalled "patent reform" bill in the Senate (S. 1145), along comes Secretary of Commerce Carlos Gutierrez (at right), trying to reenergize the IT community in Silicon Valley to push for passage of this misguided bill. Last…
-
By Kevin E. Noonan — One of the frustrations of those opposed to actions taken by the Administration over the past eight years has been the lack of Congressional oversight, in view of the congruency of the party in power of the legislative and executive branches. Although in theory this left the judicial…
-
By Donald Zuhn — Earlier today, the technology website Ars Technica posted a report that the Senate patent reform bill (S. 1145) "has been taken off the [Senate] schedule." Because Ars Technica did not provide any additional information, we sought confirmation that the bill was indeed dead — at least as far as…
-
By Donald Zuhn — In March, we reported on the lobbying expenditures for a number of biotech and pharmaceutical companies in 2007. For example, we noted that Millennium Pharmaceuticals had spent $1.28 million, Genentech $1.8 million, and AstraZeneca $4.1 million in 2007. Topping each of these companies, however, was Abbott Laboratories, based in…
-
By Kevin E. Noonan — The penchant for The New York Times‘ anti-innovation editorial policies to seamlessly blend into its "news" coverage (particularly on the Business page) has been noted by Patent Docs before. Whether the latest example is more egregious than in the past is a matter of debate, but with apologies…
-
By Donald Zuhn — On April 1st, we reported on a press release issued by the Biotechnology Industry Organization (BIO) concerning a report from the Coalition for Patent Fairness that the Senate patent reform bill (S. 1145) would soon be coming to a vote. BIO disputed this report, stating that the organization was…
-
By Donald Zuhn — On April 1st, we reported on a statement issued by Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood (at right) disputing a report from the Coalition for Patent Fairness that the Senate patent reform bill (S. 1145) would be coming to a vote in the next few weeks. …
-
By Donald Zuhn — Last week, we reported on a letter sent by Secretary of Commerce Carlos Gutierrez to Senators Patrick Leahy and Arlen Specter, in which the Secretary reaffirmed the Bush Administration’s support for the Applicant Quality Submission (AQS) provision of the Senate patent reform bill (S. 1145). In addition, Secretary Gutierrez…
-
By Donald Zuhn — Yesterday, we reported on a letter sent by Secretary of Commerce Carlos Gutierrez to Senators Patrick Leahy and Arlen Specter, in which the Secretary reaffirmed the Bush Administration’s support for Section 11 of the Senate patent reform bill (S. 1145). Section 11 would require that applicants submit Applicant Quality…
-
By Donald Zuhn — In February, we reported on a letter sent by Nathaniel Wienecke, the Assistant Secretary for Legislative and Intergovernmental Affairs of the U.S. Department of Commerce, to Senator Patrick Leahy (D-VT), Chairman of the Senate Judiciary Committee, expressing the Bush Administration’s views on the Senate patent reform bill (S. 1145). …
Patent Docs 